The immune landscape of the TH-MYCN tumour following JQ1 treatment showed an increased percentage of CD8+PD-1+, CD4+PD-1+, and Treg PD-1+ cells compared to controls, although it did not affect immune cell infiltration to the TME. The gene discussed is CD4; the disease is neoplasm.